Journal of Urgent Care Medicine

New Antiviral Flu Biologic Attracts Merck To Cidara Deal

Merck recently announced its intent to acquire Cidara Therapeutics in a deal with a total transaction value of approximately $9.2 billion. Cidara’s pipeline includes an experimental long-acting antiviral drug that has the potential to offer single-dose, universal prevention against influenza A and B. Known as “CD388,” the pipeline product is not a vaccine but a low molecular weight biologic. It is expected to offer seasonal protection for various populations, including immunocompromised individuals. The transaction is …

Veto Stops Bill to Review Healthcare Dealmaking in California

California Gov. Gavin Newsom has vetoed a bill that was designed to require state approval for healthcare merger and acquisition deals involving private investors. The scrutiny was meant to increase oversight of private equity and hedge fund ownership transactions that have the potential to lead to consolidations and closures of healthcare provider operations. However, it’s important to note the reason behind the veto. Newsom reasoned that California has an existing Office of Health Care Affordability …

Investment Trends in Urgent Care: A Mergers and Acquisitions Roundtable

Urgent message: Urgent care is a highly fragmented industry considered ripe for consolidation. A handful of high-profile deals have made 2015 the biggest year for mergers and acquisitions yet, but high valuations, oversaturated markets, changing buyer and seller expectations, and structural changes attributable to the Patient Protection and Affordable Care Act will influence urgent care deal-making in coming years. ALEXANDER NATHANSON, MD Mergers and acquisitions (M&A) in the U.S. urgent care industry have historically consisted …

Login to JUCM